ArticleCancer management and research2022

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study.

Meng Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.